248 related articles for article (PubMed ID: 37822726)
1. Tyrosine Kinase Inhibitors Plus Anti-PD-1 Antibodies with Hepatic Arterial Infusion Chemotherapy or Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma.
Yu B; Zhang N; Feng Y; Zhang Y; Zhang T; Wang L
J Hepatocell Carcinoma; 2023; 10():1735-1748. PubMed ID: 37822726
[TBL] [Abstract][Full Text] [Related]
2. Combination Therapy of Chemoembolization and Hepatic Arterial Infusion Chemotherapy in Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis Compared with Chemoembolization Alone: A Propensity Score-Matched Analysis.
Liu BJ; Gao S; Zhu X; Guo JH; Kou FX; Liu SX; Zhang X; Wang XD; Cao G; Chen H; Liu P; Zhu LZ; Xu HF; Yang RJ
Biomed Res Int; 2021; 2021():6670367. PubMed ID: 34337041
[TBL] [Abstract][Full Text] [Related]
3. Comparative study on the efficacy and safety of transarterial chemoembolization combined with hepatic arterial infusion chemotherapy for large unresectable hepatocellular carcinoma.
Yang J; Shang X; Li J; Wei N
J Gastrointest Oncol; 2024 Feb; 15(1):346-355. PubMed ID: 38482220
[TBL] [Abstract][Full Text] [Related]
4. Hepatic artery infusion chemotherapy using mFOLFOX versus transarterial chemoembolization for massive unresectable hepatocellular carcinoma: a prospective non-randomized study.
He MK; Le Y; Li QJ; Yu ZS; Li SH; Wei W; Guo RP; Shi M
Chin J Cancer; 2017 Oct; 36(1):83. PubMed ID: 29061175
[TBL] [Abstract][Full Text] [Related]
5. Comparable Clinical Outcomes Between Transarterial Chemoembolization or Hepatic Arterial Infusion Chemotherapy Combined with Tyrosine Kinase Inhibitors and PD-1 Inhibitors in Unresectable Hepatocellular Carcinoma.
Long T; Yang Z; Zeng H; Wu W; Hu Z; Yang Z; Hu D; Zhou Z; Chen M; Zhang Y
J Hepatocell Carcinoma; 2023; 10():1849-1859. PubMed ID: 37881221
[TBL] [Abstract][Full Text] [Related]
6. Clinical outcomes of hepatic arterial infusion chemotherapy combined with tyrosine kinase inhibitors and anti-PD-1 immunotherapy for unresectable intrahepatic cholangiocarcinoma.
Zhang N; Yu BR; Wang YX; Zhao YM; Zhou JM; Wang M; Wang LR; Lin ZH; Zhang T; Wang L
J Dig Dis; 2022 Aug; 23(8-9):535-545. PubMed ID: 36148493
[TBL] [Abstract][Full Text] [Related]
7. The safety and efficacy of TACE combined with HAIC, PD-1 inhibitors, and tyrosine kinase inhibitors for unresectable hepatocellular carcinoma: a retrospective study.
Huang Z; Wu Z; Zhang L; Yan L; Jiang H; Ai J
Front Oncol; 2024; 14():1298122. PubMed ID: 38318115
[TBL] [Abstract][Full Text] [Related]
8. Hepatic Arterial Infusion Chemotherapy Using Oxaliplatin Plus 5-Fluorouracil Versus Transarterial Chemoembolization/Embolization for the Treatment of Advanced Hepatocellular Carcinoma with Major Portal Vein Tumor Thrombosis.
Hu J; Bao Q; Cao G; Zhu X; Yang R; Ji X; Xu L; Zheng K; Li W; Xing B; Wang X
Cardiovasc Intervent Radiol; 2020 Jul; 43(7):996-1005. PubMed ID: 31974744
[TBL] [Abstract][Full Text] [Related]
9. Hepatic arterial infusion chemotherapy versus transarterial chemoembolization for unresectable hepatocellular carcinoma: A systematic review with meta-analysis.
Si T; Huang Z; Khorsandi SE; Ma Y; Heaton N
Front Bioeng Biotechnol; 2022; 10():1010824. PubMed ID: 36237208
[No Abstract] [Full Text] [Related]
10. [Study on the comparison of postoperative liver injury caused by hepatic arterial perfusion chemotherapy combined with targeted immunotherapy with hepatic arterial chemoembolization combined with targeted immunotherapy for intermediate-and advanced-stage liver cancer].
Li R; Li WL; Yuan GS; Pang HJ; Li Q; Hu XY; Guo YB; Chen JZ; Zang MY
Zhonghua Gan Zang Bing Za Zhi; 2023 Nov; 31(11):1163-1168. PubMed ID: 38238949
[No Abstract] [Full Text] [Related]
11. TACE-HAIC combined with targeted therapy and immunotherapy versus TACE alone for hepatocellular carcinoma with portal vein tumour thrombus: a propensity score matching study.
Yuan Y; He W; Yang Z; Qiu J; Huang Z; Shi Y; Lin Z; Zheng Y; Chen M; Lau WY; Li B; Yuan Y
Int J Surg; 2023 May; 109(5):1222-1230. PubMed ID: 37026861
[TBL] [Abstract][Full Text] [Related]
12. Hepatic arterial infusion chemotherapy combined with lenvatinib and PD-1 inhibitors versus lenvatinib and PD-1 inhibitors for HCC refractory to TACE.
Diao L; Wang C; You R; Leng B; Yu Z; Xu Q; Cheng Y; Yin G
J Gastroenterol Hepatol; 2024 Apr; 39(4):746-753. PubMed ID: 38240156
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of hepatic arterial infusion chemotherapy combined with transarterial embolization for unresectable hepatocellular carcinoma: A propensity score-matching cohort study.
Guo W; Gao J; Zhuang W; Wu Z; Li B; Chen S
JGH Open; 2020 Jun; 4(3):477-483. PubMed ID: 32514457
[TBL] [Abstract][Full Text] [Related]
14. Clinical efficacy of HAIC (FOLFOX) combined with lenvatinib plus PD-1 inhibitors vs. TACE combined with lenvatinib plus PD-1 inhibitors in the treatment of advanced hepatocellular carcinoma with portal vein tumor thrombus and arterioportal fistulas.
Lin Z; Chen D; Hu X; Huang D; Chen Y; Zhang J; Li X; Zou X
Am J Cancer Res; 2023; 13(11):5455-5465. PubMed ID: 38058801
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of transcatheter arterial chemoembolization plus hepatic arterial infusion chemotherapy in the treatment of advanced hepatocellular carcinoma with portal vein tumor thrombosis in the main trunk.
Wu Z; Gao J; Zhuang W; Yang J; Guo W
J Cancer Res Ther; 2022 Apr; 18(2):345-351. PubMed ID: 35645099
[TBL] [Abstract][Full Text] [Related]
16. Drug-Eluting Bead Transarterial Chemoembolization Combined with FOLFOX-Based Hepatic Arterial Infusion Chemotherapy for Large or Huge Hepatocellular Carcinoma.
Huang J; Huang W; Zhan M; Guo Y; Liang L; Cai M; Lin L; He M; Lian H; Lu L; Zhu K
J Hepatocell Carcinoma; 2021; 8():1445-1458. PubMed ID: 34858889
[TBL] [Abstract][Full Text] [Related]
17. Transarterial Chemoembolization Followed by Hepatic Arterial Infusion Chemotherapy Combined a Tyrosine Kinase Inhibitor for Treatment of Large Hepatocellular Carcinoma.
Chen B; Dai H; Yang J; Zhang G; Wen C; Xiang X; Lin R; Huang Y
Curr Cancer Drug Targets; 2023; 23(7):564-571. PubMed ID: 36790005
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of HepaSphere Drug-Eluting Bead Transarterial Chemoembolization Combined with Hepatic Arterial Infusion Chemotherapy as the Second-Line Treatment in Advanced Hepatocellular Carcinoma.
Liu B; Gao S; Guo J; Kou F; Liu S; Zhang X; Feng A; Wang X; Cao G; Chen H; Liu P; Xu H; Gao Q; Yang R; Xu L; Zhu X
J Hepatocell Carcinoma; 2024; 11():477-488. PubMed ID: 38463543
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of hepatic artery infusion chemotherapy combined with tyrosine kinase inhibitors plus programmed death-1 inhibitors for hepatocellular carcinoma refractory to transarterial chemoembolization.
Lin LW; Ke K; Yan LY; Chen R; Huang JY
Front Oncol; 2023; 13():1178428. PubMed ID: 37207144
[TBL] [Abstract][Full Text] [Related]
20. Comparison of Arterial Infusion Chemotherapy and Chemoembolization for Locally Advanced Hepatocellular Carcinoma: a Multicenter Retrospective Study.
Chen S; Yuan B; Yu W; Wang X; He C; Chen C
J Gastrointest Surg; 2022 Nov; 26(11):2292-2300. PubMed ID: 35920966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]